|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2400093493 |
|
最近更新日期: Date of Last Refreshed on: |
2024-12-05 17:53:10 |
|
注册时间: Date of Registration: |
2024-12-05 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
多模态图像配置计算机影像融合系统在结直肠癌肝转移微波消融术中的应用价值 |
|
Public title: |
Application of cross-modality image registration system for localising intraoperative colorectal cancer liver metastases during ablation |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
多模态图像配置计算机影像融合系统在结直肠癌肝转移微波消融术中的应用价值 |
|
Scientific title: |
Application of cross-modality image registration system for localising intraoperative colorectal cancer liver metastases during ablation |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
陈璐民 |
研究负责人: |
吴瑕 |
|
Applicant: |
Lumin Chen |
Study leader: |
Xia Wu |
|
申请注册联系人电话: Applicant telephone: |
+86 151 6823 8975 |
研究负责人电话:
Study leader's |
+86 138 5812 8795 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
chenluminest@163.com |
研究负责人电子邮件: Study leader's E-mail: |
Wuxia1981@zju.edu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
http://www.srrsh.com/ |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
|
|
申请注册联系人通讯地址: |
浙江省杭州市庆春东路3号 |
研究负责人通讯地址: |
浙江省杭州市庆春东路3号 |
|
Applicant address: |
3 East Qingchun Road, Hangzhou, China |
Study leader's address: |
3 East Qingchun Road, Hangzhou, China |
|
申请注册联系人邮政编码: Applicant postcode: |
310000 |
研究负责人邮政编码: Study leader's postcode: |
310000 |
|
申请人所在单位: |
浙江大学医学院附属邵逸夫医院 |
||
|
Applicant's institution: |
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine |
||
|
研究负责人所在单位: |
浙江大学医学院附属邵逸夫医院 |
||
|
Affiliation of the Leader: |
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
邵逸夫医院伦审2023研第0430号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
浙江大学医学院附属邵逸夫医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Run Run Shaw Hospital, Zhejiang University School of Medicine |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2023-08-02 00:00:00 | ||
|
伦理委员会联系人: |
杨漾池 |
||
|
Contact Name of the ethic committee: |
Yangchi Yang |
||
|
伦理委员会联系地址: |
浙江省杭州市庆春东路3号 |
||
|
Contact Address of the ethic committee: |
3 East Qingchun Road, Hangzhou, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 571 8600 6811 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
chenluminest@163.com |
|
研究实施负责(组长)单位: |
浙江大学医学院附属邵逸夫医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
浙江省杭州市庆春东路3号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
3 East Qingchun Road, Hangzhou, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
无 |
||||||||||||||||||||||
|
Source(s) of funding: |
none |
||||||||||||||||||||||
|
研究疾病: |
结直肠癌肝转移 |
||||||||||||||||||||||
|
Target disease: |
colorectal liver metastasis |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
回顾性研究 | ||||||||||||||||||||||
|
Study phase: |
Retrospective study |
||||||||||||||||||||||
|
研究设计: |
诊断试验诊断准确性 |
||||||||||||||||||||||
|
Study design: |
Diagnostic test for accuracy |
||||||||||||||||||||||
|
研究目的: |
验证多模态图像配置计算机影像融合系统在结直肠癌肝转移微波消融术中定位目标位置的准确性,以探索结直肠癌肝转移消融治疗的新导航方法。 |
||||||||||||||||||||||
|
Objectives of Study: |
We aimed to validate the accuracy of the automatic image registration system (AIRS) in localising target lesions throughout the CT-guided CRLM ablation procedure, thereby exploring a novel guidance method for interventional procedures. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
2022年1月-2023年5月我科行结直肠癌肝转移微波消融患者; 年龄>=18周岁; 经病理学(包括组织学或细胞学)证实为转移性结直肠肝腺癌; 临床资料齐全; 根据RECIST 1.1版本,至少有一个可评估或可测量病变的患者; |
||||||||||||||||||||||
|
Inclusion criteria |
1. Patients who underwent microwave ablation for colorectal cancer liver metastasis in our department from January 2022 to May 2023. 2. Ages >= 18 years old. 3. Confirmed as metastatic colorectal liver adenocarcinoma by pathology (including histology or cytology). 4. Complete clinical data. 5. At least one evaluable or measurable lesion according to RECIST version 1.1. |
||||||||||||||||||||||
|
排除标准: |
5年内确诊任何其他恶性肿瘤,除了局部可治疗和治愈的皮肤基底细胞癌或鳞状细胞癌,浅表性膀胱癌,宫颈原位癌,乳腺导管原位癌和甲状腺状癌; 临床资料不全者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Within 5 years, diagnosed with any other malignant tumors, except for locally treatable and curable skin basal cell carcinoma or squamous cell carcinoma, superficial bladder cancer, cervical carcinoma in situ, ductal carcinoma in situ of the breast, and papillary thyroid carcinoma. 2. Patients with incomplete clinical data. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2022-01-01 00:00:00至 To 2023-05-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2022-01-01 00:00:00 至 To 2023-05-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
结束 /Completed |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
无 |
|
Blinding: |
None |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
2024年12月上传到ResMan临床试验公共管理平台 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Upload to Clinical Trial Management Public Platform in Dec. 2024 |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
电子采集和管理系统 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Electronic Data Capture, EDC |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |